42. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, et al. (2010) Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. Journal of virology 84: 12658–12664. 43. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308: 1643–1645. 44. Matsuyama S, Taguchi F (2009) Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteol- ysis. Journal of virology 83: 11133–11141. 45. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, et al. (2004) Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proceedings of the National Academy of Sciences of the United States of America 101: 4240–4245. 46. Jaspers I, Ciencewicki JM, Zhang W, Brighton LE, Carson JL, et al. (2005) Diesel exhaust enhances influenza virus infections in respiratory epithelial cells. Toxicological sciences : an official journal of the Society of Toxicology 85: 990–1002. 47. Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, et al. (1988) Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer research 48: 1904–1909. 48. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193–199. 49. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, et al. (2005) Attenuation of equine influenza viruses through truncations of the NS1 protein. Journal of virology 79: 8431–8439. 50. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences of the United States of America 96: 9345–9350. 51. Manicassamy B, Rong L (2009) Expression of Ebolavirus glycoprotein on the target cells enhances viral entry. Virology journal 6: 75. 52. Marsh GA, Hatami R, Palese P (2007) Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. Journal of virology 81: 9727–9736. 53. Jaspers I, Zhang W, Brighton LE, Carson JL, Styblo M, et al. (2007) Selenium deficiency alters epithelial cell morphology and responses to influenza. Free radical biology & medicine 42: 1826–1837. 54. Farag-Mahmod FI, Wyde PR, Rosborough JP, Six HR (1988) Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine 6: 262–268. 55. Reed KL, Badinga L, Davis DL, Chung TE, Simmen RC (1996) Porcine endometrial glandular epithelial cells in vitro: transcriptional activities of the pregnancy-associated genes encoding antileukoproteinase and uteroferrin. Biology of reproduction 55: 469–477. 56. Hernandez ML, Harris B, Lay JC, Bromberg PA, Diaz-Sanchez D, et al. (2010) Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge. Inhalation toxicology 22: 648–656. 57. Gabrielson EW, Yu XY, Spannhake EW (1994) Comparison of the toxic effects of hydrogen peroxide and ozone on cultured human bronchial epithelial cells. Environmental health perspectives 102: 972–974. 58. Nair S, Barve A, Khor TO, Shen GX, Lin W, et al. (2010) Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulfo- raphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta pharmacologica Sinica 31: 1223–1240. 59. Shinkai Y, Sumi D, Fukami I, Ishii T, Kumagai Y (2006) Sulforaphane, an activator of Nrf2, suppresses cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. FEBS letters 580: 1771–1774. 60. Reddy NM, Kleeberger SR, Cho HY, Yamamoto M, Kensler TW, et al. (2007) Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants. American journal of respiratory cell and molecular biology 37: 3–8. 61. Na HK, Surh YJ (2008) Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 46: 1271–1278. 62. Zhu H, Jia Z, Zhang L, Yamamoto M, Misra HP, et al. (2008) Antioxidants and phase 2 enzymes in macrophages: regulation by Nrf2 signaling and protection against oxidative and electrophilic stress. Experimental biology and medicine 233: 463–474. 63. Wu CC, Hsu MC, Hsieh CW, Lin JB, Lai PH, et al. (2006) Upregulation of heme oxygenase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3- kinase/Akt and ERK pathways. Life sciences 78: 2889–2897. 64. Van Amelsvoort JM, Van Hof KH, Mathot JN, Mulder TP, Wiersma A, et al. (2001) Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica; the fate of foreign compounds in biological systems 31: 891–901. 65. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, et al. (2002) Quantitative determination of dithiocarbamates in human plasma, serum, Ozone Exposure on Influenza Infection erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clinica chimica acta; international journal of clinical chemistry 316: 43–53. 66. Friedman M, Madden MC, Samet JM, Koren HS (1992) Effects of ozone exposure on lipid metabolism in human alveolar macrophages. Environmental health perspectives 97: 95–101. 67. Pryor WA, Squadrito GL, Friedman M (1995) The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free radical biology & medicine 19: 935–941. 68. Qu F, Qin XQ, Cui YR, Xiang Y, Tan YR, et al. (2009) Ozone stress down- regulates the expression of cystic fibrosis transmembrane conductance regulator in human bronchial epithelial cells. Chemico-biological interactions 179: 219–226. 69. Bertram S, Glowacka I, Muller MA, Lavender H, Gnirss K, et al. (2011) Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. Journal of virology 85: 13363–13372. 70. Abboud RT, Vimalanathan S (2008) Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 12: 361–367. 71. Cox LA, Jr. (2009) A mathematical model of protease-antiprotease homeostasis failure in chronic obstructive pulmonary disease (COPD). Risk analysis : an official publication of the Society for Risk Analysis 29: 576–586. 72. Dillard GH, Chanutin A (1949) The protease and antiprotease of plasmas of patients with cancer and other diseases. Cancer research 9: 665–668. 73. Becker S, Soukup JM, Reed W, Carson J, Devlin RB, et al. (1998) Effect of ozone on susceptibility to respiratory viral infection and virus-induced cytokine secretion. Environmental toxicology and pharmacology 6: 257–265. 74. Purvis MR, Miller S, Ehrlich R (1961) Effect of atmospheric pollutants on susceptibility to respiratory infection. I. Effect of ozone. The Journal of infectious diseases 109: 238–242. 75. Bogadel’nikov IV, Kubyshkin AV, Gavalova NG (1990) Changes in protease inhibitor balance of the bronchoalveolar secretion in children with inflammatory lung diseases. Pediatriia. pp 17–20. 76. Garcia-Sastre A (2011) Induction and evasion of type I interferon responses by influenza viruses. Virus research 162: 12–18. 77. Mikerov AN, Umstead TM, Gan X, Huang W, Guo X, et al. (2008) Impact of ozone exposure on the phagocytic activity of human surfactant protein A (SP-A) and SP-A variants. American journal of physiology Lung cellular and molecular physiology 294: L121–130. 78. Kido H, Okumura Y, Yamada H, Le TQ, Yano M (2007) Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current pharmaceutical design 13: 405–414. 79. Hooper JD, Clements JA, Quigley JP, Antalis TM (2001) Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. The Journal of biological chemistry 276: 857–860. 80. Fischer BM, Pavlisko E, Voynow JA (2011) Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. International journal of chronic obstructive pulmonary disease 6: 413–421. 81. Liu CK, Wei G, Atwood WJ (1998) Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2–6)-linked sialic acids. Journal of virology 72: 4643–4649. 82. Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden EC, Anderson D, et al. (2003) Human-specific regulation of alpha 2–6-linked sialic acids. The Journal of biological chemistry 278: 48245–48250. 83. Mukhopadhyay S, Philip AT, Stoppacher R (2010) Pathologic findings in novel influenza A (H1N1) virus (‘‘Swine Flu’’) infection: contrasting clinical manifestations and lung pathology in two fatal cases. American journal of clinical pathology 133: 380–387. 84. Mauad T, Hajjar LA, Callegari GD, da Silva LF, Schout D, et al. (2010) Lung pathology in fatal novel human influenza A (H1N1) infection. American journal of respiratory and critical care medicine 181: 72–79. 85. Cho HY, Reddy SP, Debiase A, Yamamoto M, Kleeberger SR (2005) Gene expression profiling of NRF2-mediated protection against oxidative injury. Free radical biology & medicine 38: 325–343. 86. Zhu M, Chen Y, Li RC (2000) Oral absorption and bioavailability of tea catechins. Planta medica 66: 444–447. 87. Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, et al. (1993) Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral research 21: 289–299. 88. Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, et al. (2005) Transcription factor Nrf2 plays a pivotal role in protection against elastase- induced pulmonary inflammation and emphysema. Journal of immunology 175: 6968–6975. 89. Venkatasamy R, Spina D (2007) Protease inhibitors in respiratory disease: focus on asthma and chronic obstructive pulmonary disease. Expert review of clinical immunology 3: 365–381. PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e35108